PortViewPortView
Cybin logo

Cybin (HELP) Stock Analysis

NASDAQHealthcareMedical - Pharmaceuticals

$11.63+0.25%
1-year price historyRange $3.87 – $13.99
52-week range$11.63
$3.76$14.35

What Cybin does

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Key metrics

Market cap
$720.80M
P/E (TTM)
-2.79
EPS (TTM)
$-4.16
Beta
0.56
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$8.94
200-day avg
$6.66
52-week high
$14.35
52-week low
$3.76
CEO
Michael Halstead

ETFs linked to HELP

Broad-market and Healthcare sector ETFs an investor holding Cybin is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HELP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze HELP in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Cybin?
Cybin trades under the ticker HELP on NASDAQ.
Which exchange is HELP listed on?
HELP is listed on NASDAQ.
What sector does Cybin operate in?
Cybin is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
How can PortView help analyze HELP in a portfolio?
PortView shows HELP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.